GLOMERULAR DISEASE: Targeted steroid therapy for IgA nephropathy

    loading  Checking for direct PDF access through Ovid

Abstract

Encouraging preliminary data from the NEFIGAN trial suggest that a novel oral formulation of budesonide might reduce disease progression in IgA nephropathy. This formulation releases corticosteroid in the distal small intestine and colon, so is thought to directly target the mucosal element of the pathogenesis of the disease.

Related Topics

    loading  Loading Related Articles